Mandate

Vinge advises EQT Infrastructure IV on its acquisition of IP-Only Group AB

June 11, 2019 M&A

IP-Only owns and operates approximately 16,000 km of fiber network that, together with leased infrastructure, covers 230 of 290 municipalities in Sweden.

Vinge has advised EQT Infrastructure IV in connection with entering into an agreement to acquire 100% of the shares in IP-Only Group AB at an enterprise value of SEK 18.25 billion (EUR 1.7 billion), plus an earn-out of up to SEK 1 billion (EUR 94 million).
 
IP-Only, through its Consumer division, started a nationwide roll-out of fiber to residential customers in 2014. Today IP-Only provides wholesale fiber access services to more than 200,000 households and has a large pipeline of additional homes in progress of being delivered. EQT Infrastructure will support IP-Only in its continued contribution to achieving the Swedish Government’s broadband targets, meaning that 98 percent of the Swedish population will have broadband access by the end of 2025. 
 
The transaction is expected to close in June 2019.
 
Vinge’s team consisted of Daniel Rosvall, Karl Klackenberg, Desirée Sjöblom, Milad Kamali and Isabelle Jengsell (M&A), Louise Brorsson Salomon and Axel Jansson (Banking and Financing), Mathilda Persson and Lisa Hörnqvist (Commercial Agreements and IT), Sebastian Örndahl (Commercial Agreements, Competition and Regulatory), Kristoffer Larson (Real Property) and Daniel Wendelsson (Public Procurement).
 

Related

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024